Glycine Antagonist (GV150526) in Acute Stroke: A Multicentre, Double-Blind Placebo-Controlled Phase II Trial

Kennedy R. Lees,J.F. Lavelle,L. Cunha,H.C. Diener,E. A. C. M. Sanders,P. Tack,Per-Olov Wester

Glycine Antagonist (GV150526) in Acute Stroke: A Multicentre, Double-Blind Placebo-Controlled Phase II Trial

2001

Kennedy R. Lees
J.F. Lavelle
L. Cunha
H.C. Diener
E. A. C. M. Sanders
P. Tack
Per-Olov Wester

GV150526 is a novel glycine antagonist at the NMDA receptor complex. It is a potent neuroprotective agent in animal models of acute stroke including permanent middle cerebral artery occlusion in the r

Keywords:

Antagonist
Placebo
Glycine
Cardiology
Middle cerebral artery
NMDA receptor
Animal model
Neuroprotection
Stroke
Internal medicine
Anesthesia
Medicine
Diabetes mellitus
acute stroke
Clinical trial

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations